抄録
Recent developments in targeted therapy have forced the development of a treatment algorithm for lung cancer
based on the pathological subtype. In March 2015, the WHO classification for lung cancer was revised as the 4th
edition. The new classification was revised in consideration of clinically significant factors, such as the use of
targeted therapies, based upon genetic alterations and/or prognosis. In this section, we outline the WHO classification (4th ed.), and explain the points that have been revised for adenocarcinoma and diagnostic methods for differentiation of the pathological subtype.
